Tanja Fauti

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl et al. · Molecular Cancer Therapeutics · 2013 · 352 citations

Xenograft Models, Immunology, Immune Regulation +20

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Marina Bacac, Tanja Fauti, Johannes Sam et al. · Clinical Cancer Research · 2016 · 342 citations · Full text

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

Anja Seckinger, Jose Antonio Delgado, Samuel Moser et al. · Cancer Cell · 2017 · 305 citations · Full text

Hematological Malignancy, Cancer Immunosurveillance, Multiple Myeloma Treatment +8

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus, Claudia Ferrara, Wei Xu et al. · Science Translational Medicine · 2019 · 252 citations · Full text

miR-155 Inhibition Sensitizes CD4+ Th Cells for TREG Mediated Suppression

Heiko Stahl, Tanja Fauti, Nina D. Ullrich et al. · PLoS ONE · 2009 · 87 citations · Full text